Video
Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non—small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.